The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...

This experimental pill helped people lose about 16% of their body weight after about a year of treatment ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

You may know that dark chocolate is a good source of magnesium. Yet, this essential mineral is found in higher amounts in several other plant-based foods.

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...

Give me Deus Ex (Invisible War) ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a ...

For the first time, Bahia and Vitória face each other in a match valid for the Brasileirão Feminino A1. The clash, which takes place this Monday (16th) at 9:00 PM at the Pituaçu Stadium in ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...